micro-community-banner
  • Saved

3yr
Recap of the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Neurologists, physical medicine and rehabilitation physicians, other allied health professionals, and researchers came together for the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2022 annual meeting to learn from one another and advance the management and treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), muscular dystrophy, Duchenne muscular dystrophy, myasthenia gravis (MG), and spinal muscular atrophy.

The four-day meeting, which included plenary sessions, workshops, and social events, took place at the Gaylord Opryland Resort in Nashville, Tennessee, from Sept. 21 to 24, 2022. Click above for a post-conference wrap-up.

  • Saved

3yr
Recap of the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Neurologists, physical medicine and rehabilitation physicians, other allied health professionals, and researchers came together for the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2022 annual meeting to learn from one another and advance the management and treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), muscular dystrophy, Duchenne muscular dystrophy, myasthenia gravis (MG), and spinal muscular atrophy.

The four-day meeting, which included plenary sessions, workshops, and social events, took place at the Gaylord Opryland Resort in Nashville, Tennessee, from Sept. 21 to 24, 2022. Click above for a post-conference wrap-up.

  • Saved

3yr
Overlapping Autoimmune Neurological Syndrome: A Case Report of Triple-Positive Antibody

Overlapping Autoimmune Neurological Syndrome: A Case Report of Triple-Positive Antibody

Source : https://www.cureus.com/articles/111695-overlapping-autoimmune-neurological-syndrome-a-case-report-of-triple-positive-antibody

The presentation of several autoimmune neurological disorders in a single patient is rare and often debilitating. However, early diagnosis and efficacious treatment can lead to a significant recovery. Here, we...


Relevance: The presentation of several autoimmune neurological disorders in a single patient is rare and often debilitating. However, early diagnosis and efficacious treatment can lead to a significant recovery. Here, we present an interesting case of a triple antibody-positive autoimmune neurological syndrome patient who manifested the...

  • Saved

3yr
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis - Journal of Neurology

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis - Journal of Neurology

Source : https://link.springer.com/article/10.1007/s00415-022-11389-0

Background Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with...


Discussion: In this national MG cohort study, current IST use was a risk factor for a severe disease course of COVID-19 but not for SARS-CoV-2 infection itself. These data support the consequent implementation of effective strategies to prevent COVID-19 in this high-risk group.

  • Saved

3yr
Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients

Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients

Source : https://www.frontiersin.org/articles/10.3389/fneur.2022.961628/full

We previously found that leflunomide combined with low-dose prednisone rapidly improved the clinical symptoms of myasthenia gravis (MG), but we had not investigated the mechanism of this phenomenon. This study...


Relevance: We previously found that leflunomide combined with low-dose prednisone rapidly improved the clinical symptoms of myasthenia gravis (MG), but we had not investigated the mechanism of this phenomenon. This study documents the effect of leflunomide combined with low-dose prednisone on pro-inflammatory T cells in MG patients.